Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Can-Fite BioPharma clinical trials
The registry lists 22 studies whose lead sponsor is Can-Fite BioPharma. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 18, 2026.
Keep track of what changes. Save the Can-Fite BioPharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Can-Fite BioPharma.
- Can-Fite BioPharma22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeNot yet recruitingNCT07410455Phase 2
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNot yet recruitingNCT06643260Phase 3
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisRecruitingNCT05201404Phase 3
- Namodenoson Treatment of Advanced Pancreatic CancerRecruitingNCT06387342Phase 2
- Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)RecruitingNCT04697810Phase 2
- Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsCompletedNCT00280917Phase 2
- Safety and Efficacy Study of CF101 to Treat PsoriasisCompletedNCT00428974Phase 2
- Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)CompletedNCT02128958Phase 2
- Trial of CF101 to Treat Patients With Dry Eye DiseaseCompletedNCT01235234Phase 3
- CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCompletedNCT03168256Phase 3
- Oral CF101 Tablets Treatment in Patients With Rheumatoid ArthritisCompletedNCT01034306Phase 2
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00790218Phase 1/2
- Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureCompletedNCT01033422Phase 2
- Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis SiccaCompletedNCT00349466Phase 2
- Piclidenoson for Treatment of COVID-19CompletedNCT04333472Phase 2
- CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisTerminatedNCT02647762Phase 3
- Trial of CF101 to Treat Patients With PsoriasisCompletedNCT01265667Phase 2/3
- A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver DiseaseCompletedNCT02927314Phase 2
- Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis PatientsCompletedNCT00556894Phase 2
- A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the KneeWithdrawnNCT00837291Phase 2
- Safety &Efficacy of CF101 to Subjects With UveitisWithdrawnNCT01905124Phase 2
- A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1CompletedNCT00790673Phase 1/2